sinc
end
decemb
cluster
patient
pneumonia
unknown
origin
report
wuhan
hubei
provinc
china
share
connect
huanan
south
china
seafood
market
wuhan
confirm
diseas
caus
novel
coronaviru
provision
name
today
januari
case
confirm
china
case
also
cumul
report
taiwan
thailand
vietnam
malaysia
nepal
sri
lanka
cambodia
japan
singapor
republ
korea
unit
arab
emir
unit
state
philippin
india
australia
canada
finland
franc
germani
finland
franc
germani
european
countri
case
n
n
n
respect
report
date
accord
releas
news
case
rate
fatal
coronaviru
envelop
positivestrand
rna
virus
may
transmit
human
intermedi
host
usual
peridomest
mammal
bat
like
reservoir
view
observ
viru
divers
seventh
coronaviru
known
infect
human
four
respons
mild
upper
respiratori
tract
infect
common
cold
wherea
sever
acut
respiratori
syndrom
coronaviru
sarscov
contain
middl
east
respiratori
syndrom
coronaviru
merscov
abl
caus
atyp
pneumonia
differ
achiev
site
infect
like
depend
presenc
lower
respiratori
tract
angiotensinconvert
enzym
dipeptidyl
peptidas
main
human
receptor
surfac
glycoprotein
sarscov
merscov
respect
phylogenet
closer
sarscov
merscov
suggest
interact
main
host
receptor
albeit
possibl
lower
bind
affin
nonetheless
find
consid
also
caus
upper
respiratori
tract
infect
interact
aspect
pathogenesi
infect
deserv
investig
thoroughli
elucid
clinic
descript
first
patient
pneumonia
recent
publish
median
age
interquartil
rang
male
direct
exposur
huanan
seafood
market
regist
case
common
symptom
fever
cough
dyspnoea
present
patient
miss
requir
admiss
intens
care
unit
icu
computer
tomographi
show
bilater
pulmonari
involv
case
typic
find
multipl
area
consolid
bilater
groundglass
opac
secondari
bacteri
infect
pneumonia
bloodstream
infect
develop
patient
laboratori
result
show
leukopenia
lymphopenia
patient
respect
procalcitonin
normal
ngml
increas
serum
level
regist
studi
popul
compar
healthi
subject
higher
level
gcsf
measur
icu
nonicu
patient
suggest
possibl
role
proinflammatori
cytokin
influenc
diseas
sever
hand
increas
releas
antiinflammatori
marker
also
measur
patient
differ
previous
observ
sarscov
find
need
confirm
larger
cohort
note
laboratori
diagnosi
virusrel
cardiac
injuri
mean
increas
hypersensit
troponin
level
made
patient
overal
case
fatal
rate
tent
comparison
clinic
present
accord
first
avail
data
infect
sarscov
merscov
infect
present
tabl
first
clinic
report
use
highlight
key
issu
surround
emerg
manag
current
investig
expert
worldwid
first
search
reservoir
andor
intermedi
host
infect
spread
human
two
speci
snake
propos
possibl
wildlif
reservoir
basi
viru
codon
use
pattern
although
research
remain
sceptic
state
consist
evid
coronaviru
reservoir
mammal
bird
indic
mammal
like
link
human
fact
mani
clinic
case
expos
huanan
seafood
market
introduc
anoth
import
issu
possibl
humantohuman
transmiss
besid
exposur
infect
anim
humantohuman
transmiss
virusladen
aerosol
confirm
sarscov
regard
similar
possibl
line
fact
report
case
directli
expos
huanan
seafood
market
also
observ
case
occur
healthcar
worker
addit
exist
selfsustain
humantohuman
transmiss
support
analys
imperi
colleg
london
uk
conduct
use
mathemat
model
transmiss
recent
estim
like
updat
refin
accord
futur
trajectori
outbreak
case
infect
averag
peopl
uncertainti
rang
possibl
selfsustain
humantohuman
transmiss
plausibl
explan
scale
outbreak
wuhan
also
estim
block
transmiss
would
necessari
infectioncontrol
measur
effect
control
outbreak
question
remain
whether
asymptomat
subject
incub
infect
case
rel
mild
symptom
influenzalik
syndrom
neither
necessit
search
care
abl
effect
transmit
viru
human
sinc
may
complic
delay
effect
infectioncontrol
measur
hand
larg
pool
mild
case
could
explain
current
report
low
case
fatal
rate
press
news
lower
case
fatal
rate
observ
hospit
patient
pneumonia
describ
publish
report
probabl
better
repres
subpopul
patient
sever
clinic
present
rather
entir
popul
patient
overal
crude
mortal
like
lower
worth
note
also
case
fatal
rate
report
press
news
lower
previous
describ
sarscov
merscov
infect
respect
final
promis
effect
observ
anim
model
sarscov
merscov
infect
antivir
remdesivir
lopinavirritonavir
guid
evalu
randomis
control
trial
assess
efficaci
safeti
lopinavirritonavir
hospit
patient
infect
initi
china
clinic
present
fever
cough
dyspnoea
frequent
sign
symptom
diarrhoea
observ
patient
fever
cough
chill
rigour
frequent
sign
symptom
short
breath
diarrhoea
observ
patient
respect
fever
chill
rigor
cough
frequent
sign
symptom
short
breath
diarrhoea
observ
patient
respect
leukopenia
lymphopenia
thrombocytopenia
high
lactat
dehydrogenas
leukopenia
lymphopenia
thrombocytopenia
high
lactat
dehydrogenas
leukopenia
lymphopenia
thrombocytopenia
high
lactat
dehydrogenas
radiolog
ct
abnorm
report
typic
find
bilater
multipl
lobular
subsegment
area
consolid
icu
patient
bilater
groundglass
opac
subsegment
area
consolid
nonicu
patient
chest
radiographi
ct
abnorm
report
typic
find
unilateralbilater
groundglass
opac
focal
unilateralbilater
consolid
abnorm
tend
progress
bilater
consolid
hospit
patient
chest
radiographi
ct
abnorm
report
typic
find
unilateralbilater
patchi
densiti
infiltr
bilater
hilar
infiltr
segmentedlobar
opac
groundglass
opac
possibl
small
pleural
effus
lower
lobe
gener
affect
upper
lobe
earli
cours
ill
rapid
radiograph
progress
sar
abbrevi
cov
coronaviru
ct
computer
tomographi
icu
intens
care
unit
mer
middl
east
respiratori
syndrom
sar
sever
acut
respiratori
syndrom
report
inform
first
publish
seri
hospit
patient
elucid
aspect
critic
perfection
contain
transmiss
clinic
approach
patient
infect
tent
algorithm
clinic
approach
sever
case
propos
figur
add
alreadi
occur
rapid
concert
respons
rapidli
evolv
outbreak
local
global
author
organ
research
china
worldwid
overal
result
import
inform
characterist
viru
rapidli
becom
avail
may
improv
contain
manag
effort
exampl
genom
sequenc
publicli
share
day
molecular
diagnost
platform
identifi
rapidli
develop
time
need
develop
vaccin
expect
shorter
month
compar
month
time
sarscov
outbreak
recent
highlight
anthoni
fauci
colleagu
although
true
trajectori
outbreak
still
imposs
predict
rapid
global
concert
prepar
respons
also
term
clinic
manag
remain
essenti
effect
counteract
novel
emerg
viral
infect
regard
like
case
europ
ensur
firm
time
detect
f
g
u
r
e
possibl
diagnostictherapeut
algorithm
accord
current
avail
inform
patient
suspect
pneumonia
abbrevi
cov
coronaviru
icu
intens
care
unit
ivig
intraven
immunoglobulin
pcr
polymeras
chain
reaction
current
standard
therapeut
recommend
lopinavirritonavir
avail
sever
hospit
shown
promis
result
preclin
model
case
seri
sarscov
merscov
infect
although
highlevel
evid
efficaci
safeti
current
avail
use
either
monotherapi
combin
interferon
drug
random
control
trial
initi
patient
pneumonia
china
conflict
result
report
previou
experi
use
ribavirin
sever
pulmonari
infect
caus
coronavirus
wherea
promis
preclin
model
exist
remdesivir
drug
approv
indic
loperamid
chloroquin
chlorpromazin
cyclosporin
mycophenol
acid
shown
activ
coronaviru
vitro
role
therapi
human
diseas
remain
debat
also
view
immunosuppress
effect
cyclosporin
mycophenol
acid
although
absenc
highlevel
evid
use
plasma
convalesc
patient
could
consid
follow
previou
experi
merscovinfect
subject
prefer
dedic
investig
patient
